Physician profile
Ravinder Singh
NPI 1447289962
$8,442.33
in general payments reported to CMS, 2019-2025
43 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,948 · 2020: $986 · 2021: $1,162 · 2022: $853 · 2023: $1,249 · 2024: $1,115 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,400 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,399.81 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,313.27 | 2019-2025 | Freestyle Libre 3 |
| Pfizer INC. | $1,001.84 | 2019-2025 | |
| Abbvie INC. | $916.56 | 2019-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $671.61 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $535.08 | 2019-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $529.76 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $453.79 | 2019-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $362.82 | 2019-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $340.33 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.59 | 2019-2024 | Jardiance |
| Allergan, INC. | $253.21 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.47 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $185.74 | 2019-2022 | |
| Astellas Pharma US INC | $181.29 | 2019-2023 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $164.37 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.